PMV PHARMACEUTICALS, INC. Stock-Based Compensation
PMV PHARMACEUTICALS, INC. (PMVP) reported Stock-Based Compensation of $2.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.54M, a 7.49% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.39M, a 7.69% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.36M, a 7.40% increase year-over-year.
- PMV PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.38M, a 37.81% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $5.92M, a 33.23% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $8.87M, a 28.31% decline from fiscal 2023.
- PMV PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $12.38M, a 21.38% increase from fiscal 2022.
- PMV PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $10.20M, a 90.92% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.94M 10-Q · filed 2026-08-14 | $4.30M derived: sum of 3 quarters · filed 2026-08-14 | $5.68M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.39M 10-Q · filed 2026-05-12 | $2.76M derived: sum of 2 quarters · filed 2026-05-12 | $4.14M derived: sum of 3 quarters · filed 2026-05-12 | $5.81M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $2.75M derived: sum of 2 quarters · filed 2026-03-06 | $4.42M derived: sum of 3 quarters · filed 2026-08-14 | $5.92M 10-K · filed 2026-03-06 |
| 2025-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.05M derived: sum of 2 quarters · filed 2026-08-14 | $4.56M 10-Q · filed 2025-11-12 | $5.83M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $3.18M 10-Q · filed 2026-08-14 | $4.45M derived: sum of 3 quarters · filed 2026-08-14 | $6.67M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.51M 10-Q · filed 2026-05-12 | $2.78M derived: sum of 2 quarters · filed 2026-05-12 | $5.00M derived: sum of 3 quarters · filed 2026-05-12 | $7.77M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $3.50M derived: sum of 2 quarters · filed 2026-03-06 | $6.26M derived: sum of 3 quarters · filed 2026-03-06 | $8.87M 10-K · filed 2026-03-06 |
| 2024-09-30 | $2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.99M derived: sum of 2 quarters · filed 2025-11-12 | $7.60M 10-Q · filed 2025-11-12 | $10.57M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.38M 10-Q · filed 2025-08-07 | $8.34M derived: sum of 3 quarters · filed 2026-03-06 | $11.67M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $2.61M 10-Q · filed 2025-05-09 | $5.58M derived: sum of 2 quarters · filed 2026-03-06 | $8.90M derived: sum of 3 quarters · filed 2026-03-06 | $12.05M derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $6.29M derived: sum of 2 quarters · filed 2026-03-06 | $9.44M derived: sum of 3 quarters · filed 2026-03-06 | $12.38M 10-K · filed 2026-03-06 |
| 2023-09-30 | $3.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.48M derived: sum of 2 quarters · filed 2024-11-07 | $9.41M 10-Q · filed 2024-11-07 | $12.46M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.08M 10-Q · filed 2024-08-08 | $9.14M derived: sum of 3 quarters · filed 2025-03-03 | $11.59M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $2.93M 10-Q · filed 2024-05-09 | $5.98M derived: sum of 2 quarters · filed 2025-03-03 | $8.43M derived: sum of 3 quarters · filed 2025-03-03 | $10.95M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $5.50M derived: sum of 2 quarters · filed 2025-03-03 | $8.02M derived: sum of 3 quarters · filed 2025-03-03 | $10.20M 10-K · filed 2025-03-03 |
| 2022-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.97M derived: sum of 2 quarters · filed 2023-11-09 | $7.14M 10-Q · filed 2023-11-09 | $8.91M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $4.70M 10-Q · filed 2023-08-09 | $6.46M derived: sum of 3 quarters · filed 2024-02-29 | $8.26M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $2.18M 10-Q · filed 2023-05-10 | $3.94M derived: sum of 2 quarters · filed 2024-02-29 | $5.74M derived: sum of 3 quarters · filed 2024-02-29 | $6.89M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.56M derived: sum of 2 quarters · filed 2024-02-29 | $4.71M derived: sum of 3 quarters · filed 2024-02-29 | $5.34M 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.95M derived: sum of 2 quarters · filed 2022-11-08 | $3.57M 10-Q · filed 2022-11-08 | $4.16M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.78M 10-Q · filed 2022-08-09 | $2.36M derived: sum of 3 quarters · filed 2023-03-01 | $3.03M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $627.00K 10-Q · filed 2022-05-10 | $1.21M derived: sum of 2 quarters · filed 2023-03-01 | $1.88M derived: sum of 3 quarters · filed 2023-03-01 | $2.26M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $584.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.25M derived: sum of 2 quarters · filed 2023-03-01 | $1.64M derived: sum of 3 quarters · filed 2023-03-01 | $1.93M 10-K · filed 2023-03-01 |
| 2020-09-30 | $670.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.05M derived: sum of 2 quarters · filed 2021-11-12 | $1.35M 10-Q · filed 2021-11-12 | $1.59M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $383.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $679.00K 10-Q · filed 2021-08-13 | $918.00K derived: sum of 3 quarters · filed 2022-03-01 | |
| 2020-03-31 | $296.00K 10-Q · filed 2021-05-14 | $535.00K derived: sum of 2 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $239.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $908.00K 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $669.00K 10-Q · filed 2020-11-13 | |||
| 2018-12-31 | $1.08M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |